Infusional cancer chemotherapy: Historical evolution and future development at the cancer center of Boston

Cancer Investigation

Volumn 13, Issue 2, 1995, Pages 202-226

  Lokich, Jacob ^a   Anderson, Norwood ^a  

^a Cancer Center of Boston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLOXURIDINE; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; MESNA; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; PENTOSTATIN; STREPTOZOCIN; THIOTEPA; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG INFUSION; DRUG STABILITY; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

AMBULATORY CARE FACILITIES; ANTINEOPLASTIC AGENTS; BOSTON; CANCER CARE FACILITIES; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DRUG STABILITY; HUMAN; INFUSION PUMPS, IMPLANTABLE; INFUSIONS, PARENTERAL; MEDICAL ONCOLOGY; NEOPLASMS; SUPPORT, NON-U.S. GOV'T;

EID: 0028906820     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909509011691     Document Type: Article

References (72)

1. The clinical effects of the continuous administration of fluorinated pyrimidines (5-fluo-rouracil and 5-fluoro-2′-deoxyuridine)
2. The clinical effects of the continuous and intra-arterial infusion of cancer chemotherapeutic compounds
3. Dose: A critical factor in cancer chemotherapy
4. Ifosfamide plus doxorubicin in metastatic adult sarcomas: A multi-institutional phase II trial
5. Pharmaceutical issues in infusion chemotherapy stability and compatibility
6. A review of the stability and compatibility of antineoplastic drugs for multiple-drug infusions
7. Cellular basis for the inefficacy of 5-fluorouracil in human colon carcinoma
8. A comparison of 5-fluorouracil administered by slow infusion and rapid Injection
9. Phase I study of protracted venous infusion of 5-fluorouracil
10. Chemotherapy associated palmar-plantar erythrodysesthesia syndrome
11. 5-Fluorouracil infusional schedules
12. A preliminary comparison of 5-fluoro-2′deoxyuridine administered by rapid daily intravenous injections and by slow continuous infusion
13. Phase I study of continuous venous infusion of floxuridine (5-FUdR) chemotherapy
14. Radiologic manifestations of small bowel toxicity due to floxuridine therapy
15. Comparison of 5-fluorouracil and 2′deoxy-5-fluorouridine in treatment of patients with advanced adenocarcinoma of the colon or rectum
16. A phase I and pharmacology study of continuous infusion low-dose methotrexate administration
17. Phase I–II study of c/j-diamminedichloroplatinum (II) administered by constant 5-day infusion
18. Phase I study of protracted infusion of cisplatin
19. Protracted low-dose cis-platin infusion in advanced colorectal cancer
20. Prolonged venous infusion of cisplatin and concurrent radiation therapy for lung carcinoma
21. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy
22. Infusional carboplatin: Phase I studies of 5 day and 14 day infusions
23. A phase II trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia
24. Continuous infusion carboplatin on a 21-day schedule. A phase I and pharmacokinetic study. J
25. Alkylating agents with infusional schedules of delivery
26. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo
27. Phase I study of continuous infusion cyclophosphamide for protracted durations
28. Infusional cyclophosphamide for resistant lymphoma
29. Classical CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer
30. Ifosfamide continuous infusion without mesna: A phase I trial of a 14-day cycle
31. A phase I study of thiotepa administered by short-term and protracted continuous intravenous infusion
32. Streptozotocin for metastatic malignant melanoma
33. Mitomycin C; Phase I study of a constant infusion ambulatory treatment schedule
34. Constant infusion schedule for adriamycin: A phase I–II clinical trial of a 30-day schedule by ambulatory pump delivery system
35. Clinical pharmacology of continuous infusion doxorubicin
36. Infusional schedules for antitumor antibiotics
37. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer
38. Phase I study of VP-16–213 administered as a continuous five day infusion
39. Multi drug infusional chemotherapy using admixtures
40. Protracted vinblastine infusion phase I–II study in malignant melanoma and other tumors
41. Infusional cisplatin plus cyclophosphamide in advanced ovarian cancer
42. Mitomycin C (MMC) for treatment of measurable colorectal carcinoma (CRC) resistant to 5fluorouracil (FU)
43. A comparative trial of three schedules for single-agent doxorubicin in advanced breast cancer: An aborted investigation
44. Phase II study of VP16–213 (etoposide) in refractory metastatic breast carcinoma
45. Comparison of continuously infused 5fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma
46. A prospective randomized comparison of continuous infusional 5-fluorouracil with a conventional bolus schedule in metastatic colorectal cardinoma: A Mid Atlantic Oncology Program Study
47. A pilot study of protracted venous infusion of 5fluorouracil and concomitant radiation therapy
48. Concomitant 5fluorouracil infusion and high dose radiation therapy for stage III non small cell lung cancer
49. Sequential infusional 5fluorouracil followed by concomitant radiation therapy for tumors of the esophagus and gastroesophageal junction
50. Treatment of locoregional esophageal cancer
51. Combined floxuridine and cisplatin in a fourteen day infusion
52. Combined Sfluorouracil and floxuridine administered as a 14-day infusion
53. Doxorubicin/vinblastine and doxorubicin/cyclophosphamide combination chemotherapy by continuous infusion
54. Etoposide admixed with cisplatin
55. Combination chemotherapy using etoposide and platinum or carboplatin for metastatic carcinoma to brain
56. Etoposide plus cisplatin by 72 hour infusion for non small cell lung cancer
57. Etoposide plus carboplatin admixture: Phase I study of five or seven day continuous infusion
58. Pilot study of ambulatory infusional ifosfamide admixed with carboplatin
59. Cyclophosphamide, methotrexate, and 5-fluorouracil in a three-drug admixture
60. Infusion of floxuridine plus etoposide plus cisplatin in human malignancies
61. Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and nack
62. Multi-drug infusion of 5fluorouracil, leucovorin and platinum (PLF). An analysis of leucovorin dosing
63. A phase II trial of PFL in advanced NSCLC
64. Treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with infusional carboplatin (C), ifosfamide (I), mesna (M) and etoposide (E)
65. 5Fluorouracil and methotrexate administered simultaneously as a continuous infusion: A phase I study
66. A phase I clinical trial of combined fluoropyrimidines with leucovorin in a 14-day infusion
67. Dual modulation of 5fluorouracil using leucovorin and hydroxyurea
68. Controversial issues in 5-fluorouracil infusion use
69. Black holes and billed charges: An analysis of infusional therapy costs
70. Sixteen-week dose intense chemotherapy in the adjuvant treatment of breast cancer
71. Clinical pharmacokinetics of suramin therapy